Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Imaging Reports
Published in: Current Cardiovascular Imaging Reports 1/2011

01-02-2011

Molecular MRI of Thrombosis

Authors: Katie L. Ciesienski, Peter Caravan

Published in: Current Cardiovascular Imaging Reports | Issue 1/2011

Login to get access

Abstract

This review focuses on recent approaches in using targeted MRI probes for noninvasive molecular imaging of thrombosis. Probe design strategies are discussed: choice of molecular target; nanoparticle versus small-molecule probe; and gadolinium versus iron oxide imaging reporter. Examples of these different design strategies are chosen from the recent literature. Novel contrast agents used to image direct and indirect binding to fibrin have been described as well as direct binding to activated platelets. Emphasis is placed on probes where utility has been demonstrated in animal models or in human clinical trials.
Literature
1.
2.
Guercini, F., M. Acciarresi, G. Agnelli, et al.: Cryptogenic stroke: Time to determine aetiology. J Thromb Haemost 2008, 6:549–554.CrossRefPubMed
3.
Di Tullio, M. R., C. Russo, Z. Jin, et al.: Aortic arch plaques and risk of recurrent stroke and death. Circulation 2009, 119:2376–2382.CrossRefPubMed
4.
Mazighi, M., J. Labreuche, F. Gongora-Rivera, et al.: Autopsy prevalence of intracranial atherosclerosis in patients with fatal stroke. Stroke 2008, 39:1142–1147.CrossRefPubMed
5.
Mazighi, M., J. Labreuche, F. Gongora-Rivera, et al.: Autopsy prevalence of proximal extracranial atherosclerosis in patients with fatal stroke. Stroke 2009, 40:713–718.CrossRefPubMed
6.
Overell, J. R., I. Bone and K. R. Lees: Interatrial septal abnormalities and stroke: A meta-analysis of case-control studies. Neurology 2000, 55:1172–1179.PubMed
7.
Amarenco, P., C. Duyckaerts, C. Tzourio, et al.: The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 1992, 326:221–225.CrossRefPubMed
8.
Amarenco, P., A. Cohen, C. Tzourio, et al.: Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994, 331:1474–1479.CrossRefPubMed
9.
Tunick, P. A., B. P. Rosenzweig, E. S. Katz, et al.: High risk for vascular events in patients with protruding aortic atheromas: A prospective study. J Am Coll Cardiol 1994, 23:1085–1090.CrossRefPubMed
10.
Jones, E. F., J. M. Kalman, P. Calafiore, et al.: Proximal aortic atheroma. An independent risk factor for cerebral ischemia. Stroke 1995, 26:218–224.PubMed
11.
Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The french study of aortic plaques in stroke group. N Engl J Med 1996, 334:1216–1221.
12.
Di Tullio, M. R., R. L. Sacco, D. Gersony, et al.: Aortic atheromas and acute ischemic stroke: A transesophageal echocardiographic study in an ethnically mixed population. Neurology 1996, 46:1560–1566.PubMed
13.
Mitusch, R., C. Doherty, H. Wucherpfennig, et al.: Vascular events during follow-up in patients with aortic arch atherosclerosis. Stroke 1997, 28:36–39.PubMed
14.
Fujimoto, S., M. Yasaka, R. Otsubo, et al.: Aortic arch atherosclerotic lesions and the recurrence of ischemic stroke. Stroke 2004, 35:1426–1429.CrossRefPubMed
15.
Tanaka, M., M. Yasaka, K. Nagano, et al.: Moderate atheroma of the aortic arch and the risk of stroke. Cerebrovasc Dis 2006, 21:26–31.CrossRefPubMed
16.
Meissner, I., B. K. Khandheria, S. G. Sheps, et al.: Atherosclerosis of the aorta: Risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study. J Am Coll Cardiol 2004, 44:1018–1024.CrossRefPubMed
17.
Russo, C., Z. Jin, T. Rundek, et al.: Atherosclerotic disease of the proximal aorta and the risk of vascular events in a population-based cohort: The aortic plaques and risk of ischemic stroke (apris) study. Stroke 2009, 40:2313–2318.CrossRefPubMed
18.
Bosnjakovic, V. B., B. D. Jankovic, J. Horvat, et al.: Radiolabeled anti-human fibrin antibody: A new thrombus-detecting agent. Lancet 1977, 8009:452–454.CrossRef
19.
Harwig, S. S. L., J. F. Harwig and M. J. Welch: Preparation of technetium-99m-labeled fibrinogen. J. Nucl. Med. 1976, 17:151–152.PubMed
20.
Balu, N., J. Wang, L. Dong, et al.: Current techniques for MR imaging of atherosclerosis. Top Magn Reson Imaging 2009, 20:203–215.CrossRefPubMed
21.
Underhill, H. R., T. S. Hatsukami, Z. A. Fayad, et al.: MRI of carotid atherosclerosis: Clinical implications and future directions. Nat Rev Cardiol 2010, 7:165–173.CrossRefPubMed
22.
Wang, J., N. Balu, G. Canton, et al.: Imaging biomarkers of cardiovascular disease. J Magn Reson Imaging 2010, 32:502–515.CrossRefPubMed
23.
Marder, V. J., D. J. Chute, S. Starkman, et al.: Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke 2006, 37:2086–2093.CrossRefPubMed
24.
Spuentrup, E., B. Fausten, S. Kinzel, et al.: Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation 2005, 112:396–399.CrossRefPubMed
25.
Spuentrup, E., M. Katoh, A. Buecker, et al.: Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol 2007, 42:586–595.CrossRefPubMed
26.
Botnar, R. M., A. S. Perez, S. Witte, et al.: In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 2004, 109:2023–2029.CrossRefPubMed
27.
Overoye-Chan, K., S. Koerner, R. J. Looby, et al.: EP-2104R: A fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. J Am Chem Soc 2008, 130:6025–6039.CrossRefPubMed
28.
Botnar, R. M., A. Buecker, A. J. Wiethoff, et al.: In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 2004, 110:1463–1466.CrossRefPubMed
29.
Spuentrup, E., M. Katoh, A. J. Wiethoff, et al.: Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent. Am J Respir Crit Care Med 2005, 172:494–500.CrossRefPubMed
30.
Stracke, C. P., M. Katoh, A. J. Wiethoff, et al.: Molecular MRI of cerebral venous sinus thrombosis using a new fibrin-specific MR contrast agent. Stroke 2007, 38:1476–1481.CrossRefPubMed
31.
Katoh, M., P. Haage, A. J. Wiethoff, et al.: Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: A feasibility study. Invest Radiol 2009, 44:146–150.CrossRefPubMed
32.
Spuentrup, E., A. Buecker, M. Katoh, et al.: Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 2005, 111:1377–1382.CrossRefPubMed
33.
Sirol, M., V. Fuster, J. J. Badimon, et al.: Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 2005, 112:1594–1600.CrossRefPubMed
34.••
Vymazal, J., E. Spuentrup, G. Cardenas-Molina, et al.: Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: Results of a phase II clinical study of feasibility. Invest Radiol 2009, 44:697–704. This paper describes the results of a 52-patient phase 2 feasibility study. Patients with known thrombus in one of six vascular territories were imaged pre and post contrast agent. EP-2104R–enhanced MRI detected both thrombi not readily visible precontrast screening and gave additional enhancement of thrombi that are visible in precontrast imaging.CrossRefPubMed
35.••
Spuentrup, E., R. M. Botnar, A. J. Wiethoff, et al.: MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: Initial results in patients. Eur Radiol 2008, 18:1995–2005. First examples of molecular MRI of thrombus in patients. Bright spot imaging with the fibrin-targeted gadolinium probe EP-2104R.CrossRefPubMed
36.•
Uppal, R., I. Ay, G. P. Dai, et al.: Molecular MRI of intracranial thrombus in a rat ischemic stroke model. Stroke 2010, 41:1271–1277. This paper shows that EP-2104R–enhanced MRI can successfully identify intracranial thrombus in a rat embolic stroke model. It demonstrates efficacy of this probe at high fields and in small animal models. Fresh as well as aged thrombi are visualized.CrossRefPubMed
37.
Flacke, S., S. Fischer, M. J. Scott, et al.: Novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation 2001, 104:1280–1285.CrossRefPubMed
38.
Winter, P. M., S. D. Caruthers, X. Yu, et al.: Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med 2003, 50:411–416.CrossRefPubMed
39.
Pan, D., S. D. Caruthers, G. Hu, et al.: Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc 2008, 130:9186–9187.CrossRefPubMed
40.
Pan, D. P. J., A. Senpan, S. D. Caruthers, et al.: Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem Commun 2009, 3234–3236.
41.•
Miserus, R.-J. J. H. M., M. V. Herias, L. Prinzen, et al.: Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovasc Imaging 2009, 2:987–996. This is an example of using factor XIII as a signal amplification strategy. Gadolinium-based probes using an α 2 -antiplasmin motif are covalently attached to fibrin in vivo by the action of factor XIII. Two-photon microscopy of the bimodal contrast agent confirmed mechanism of action. This probe was effective at imaging early, but not late or organized thrombus.CrossRefPubMed
42.•
McCarthy, J. R., P. Patel, I. Botnaru, et al.: Multimodal nanoagents for the detection of intravascular thrombi. Bioconj Chem 2009, 20:1251–1255. This paper discusses fluorescently labeled magnetic nanoparticles targeted to fibrin and activated factor XIII. Both nanoagents possess high affinities for thrombi in vivo, and enable multimodal fluorescence and MRI.CrossRef
43.
Klink, A., E. Lancelot, S. Ballet, et al.: Magnetic resonance molecular imaging of thrombosis in an arachidonic acid mouse model using an activated platelet targeted probe. Arterioscler Thromb Vasc Biol. 2010, 30:403–410.CrossRefPubMed
44.••
von zur Muhlen, C., D. von Elverfeldt, J. A. Moeller, et al.: Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 2008, 118:258–267. This is an antibody–iron oxide approach to imaging activated platelets. Binding to activated platelets was demonstrated ex vivo to the surface of symptomatic human carotid plaques and in mouse models of thrombosis and thrombolysis.CrossRef
Metadata
Title
Molecular MRI of Thrombosis
Authors
Katie L. Ciesienski
Peter Caravan
Publication date
01-02-2011
Publisher
Current Science Inc.
Published in
Current Cardiovascular Imaging Reports / Issue 1/2011
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-010-9061-5

Other articles of this Issue 1/2011

Current Cardiovascular Imaging Reports 1/2011 Go to the issue

ReviewPaper

Imaging of Oxidation-Specific Epitopes in Atherosclerosis and Macrophage-Rich Vulnerable Plaques

ReviewPaper

Microparticle-Based Molecular MRI of Atherosclerosis, Thrombosis, and Tissue Ischemia

ReviewPaper

Cellular and Functional Imaging of Cardiac Transplant Rejection

ReviewPaper

Emerging Approaches for Cardiovascular Stem Cell Imaging

ReviewPaper

Noninvasive Positron Emission Tomography Imaging of Coronary Arterial Inflammation

ReviewPaper

Imaging Myeloperoxidase Activity in Cardiovascular Disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits